Retroviral vector design for gene therapy of cancer: Specific inhibition and tagging of BCR-ABL(p190) cells

Molecular Medicine

Volumn 2, Issue 1, 1996, Pages 125-133

  Garcia Hernandez B ^a   Sanchez Garcia I ^a,b  

^a Instituto de Biología Funcional y Genómica and Departamento de Microbiología y Genética   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BARIUM; BCR ABL PROTEIN; CD5 ANTIGEN; COMPLEMENTARY DNA; INTERLEUKIN 3; ANTINEOPLASTIC AGENT; COMPLEMENTARY RNA; MEMBRANE PROTEIN; MESSENGER RNA;

ANIMAL CELL; ARTICLE; CANCER THERAPY; CLONING VECTOR; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; HEMATOPOIETIC CELL; MOUSE; NONHUMAN; PICORNAVIRUS; PRIORITY JOURNAL; RETROVIRUS; SIGNAL TRANSDUCTION; CELL DIVISION; CELL LINE; CHEMISTRY; DRUG ANTAGONISM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC MARKER; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; NEOPLASM; NUCLEOTIDE SEQUENCE;

ANTIGENS, CD5; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL DIVISION; CELL LINE; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC MARKERS; GENETIC VECTORS; HUMANS; INTERLEUKIN-3; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; NEOPLASMS; RETROVIRIDAE; RNA, ANTISENSE; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 0029678661     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03402208     Document Type: Article

References (26)

1. Szczylik C, Skorski T, Nicolaides NC, et al. (1991) Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 253: 562-565.
2. Skorski T, Nieborowska-Skorska M, Nicolaides NC, et al. (1994) Suppression of Philadelphia leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci. U.S.A. 91: 4504-4508.
3. Choo Y, Sánchez-García I, Klug A. (1994) In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence. Nature 372: 642-645.
4. Sánchez-García I, Rabbitts TH. (1993) LIM proteins in leukaemia and development. Semin Cancer Biol. 4: 349-358.
5. Sánchez-García I, Rabbitts TH. (1994) Transcriptional activation by TAL1 and FUS-CHOP proteins expressed in acute malignancies as a result of chromosomal abnormalities. Proc. Natl. Acad. Sci. U.S.A. 91: 7869-7873.
6. Sánchez-García I. (in press) Consequences of chromosomal abnormalities in tumour development explained? TIBS.
7. Heisterkamp N, Jenster G, Hoeve HT, Zovich D, Pattengale PK, Groffen J. (1990) Acute leukaemia in bcr/abl transgenic mice. Nature 344: 251-253.
8. Konopka JB, Watanabe SM, Witte ON. (1984) An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37: 1035-1042.
9. Shtivelman E, Lifshitz B, Gale RP, Canaani E. (1985) Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315: 550-554.
10. Mes-Masson A-M, McLaughlin J, Daley GQ, Paskind M, Witte ON. (1986) Overlapping cDNA clones define the complete coding region for the P210bcr-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome. Proc. Natl. Acad. Sci. U.S.A. 83: 9768-9772.
11. 1-positive ALL. Science 235: 85-88.
12. Daley CG, McLaughlin J, Witte ON, Baltimore D. (1987) The CML-specific P210 bcr/abl, unlike v-abl, does not transform NIH/3T3 fibroblasts. Science 237: 532-535.
13. Hermans A, et al. (1987) Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 51: 33-40.
14. Elefanty AG, Hariharn IK, Cory S. (1990) bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haematopoietic neoplasms in mice. EMBO J. 9: 1069-1078.
15. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. (1990) Induction of a chronic leukaemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. U.S.A. 87: 6649-6653.
16. Gishizky ML, Johnson-White J, Witte ON. (1993) Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome. Proc. Natl. Acad. Sci. U.S.A. 90: 3755-3759.
17. Lugo TG, Pendergast AM, Muller AJ, Witte ON. (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079-1082.
18. Dhut S, Chaplin T, Young BD. (1991) Normal c-abl gene protein - A nuclear component. Oncogene 6: 1459-1464.
19. McWhirter JR, Wang JYJ. (1991) Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol. Cell. Biol. 11: 1553-1565.
20. McLaughlin J, Chianese E, Witte ON. (1989) Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol. Cell. Biol. 9: 1866-1889.
21. Sánchez-García I, Grütz G. (1995) Tumorigenic activity of the BC-ABL oncogenes is mediated by BCL2. Proc. Natl. Acad. Sci. U.S.A. 92: 5287-5291.
22. Wagner RW. (1994) Gene inhibition using antisense oligo deoxynucleotides. Nature 372: 333-335.
23. Dranoff G, Jaffee E, Lazenby A, et al. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90: 3539-3543.
24. Ghattas IR, Sanes JR, Majors JE. (1991) The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol. Cell. Biol. 11: 5848-5859.
25. Palacios R, Steinmetz M. (1985) IL-3 dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41: 727-734.
26. bcr-abl protein. Proc. Natl. Acad. Sci. U.S.A. 85: 9312-9316.